Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 17, 2018
Pharmacy Choice - News - U.S. Pharmaceutical Industry - July 17, 2018

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/17/18 - Allergy Immunotherapy Market Blatant Growth with USD 4,324.7 million | with Foremost Players like Allergy Therapeutics, Circassia, DBV Technologies, etc. by 2023 Says MRFR
Along with this regional analysis of the market which includes America, Europe, Asia Pacific and Middle East and Africa.. The market is expected to grow at the CAGR of~ 10.85% during the forecast period and is estimated to reach USD 4,324.7 million by 2023.. Some of the key players in this market are: ALK Abello A/S, Allergy Therapeutics, Circassia
7/17/18 - U.S. Approves New Drug To Treat Smallpox To Counter Risk Of Bio-Terrorism [Daily Independent (Nigeria)]
The U.S. Food and Drug Administration has approved the new drug tecovirimat to treat smallpox, the first drug against the deadly disease since a huge vaccination campaign over three decades ago. To address the risk of bio-terrorism, Congress has taken steps to enable the development and approval of countermeasures to thwart pathogens that
7/16/18 - "Dosage Form Comprising an Active Ingredient and a Plurality of Solid Porous Microcarriers" in Patent Application Approval Process (USPTO 20180177806)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventor Yamamoto, Akira, filed on February 26, 2018, was made available online on July 5, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or institution
7/16/18 - "Hair Removal Compositions and Methods" in Patent Application Approval Process (USPTO 20180177700)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventor ROTUNDA, ADAM M., filed on December 28, 2016, was made available online on July 5, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or institutio
7/16/18 - "Pharmaceutical Compositions" in Patent Application Approval Process (USPTO 20180177719)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Jones, Alan; Rodriguez, Cesar; Henzler, David; Currington, Jeff; Sharma, Megha; Aldrich, Daniel; Currington, Cameron; Sloane, Michael, filed on February 21, 2016, was made available online on July 5, 2018, according to news reporting originating fro
7/16/18 - "Raman Spectroscopic Structure Investigation of Proteins Dispersed in a Liquid Phase" in Patent Application Approval Process (USPTO 20180180549)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventor Lewis, E. Neil, filed on March 25, 2015, was made available online on July 5, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. The following quote was obtained by the news editors from the background info
7/16/18 - 2018 and Beyond: Canada Pharmaceutical & Healthcare Market Trends & Outlook Study to 2025 - ResearchAndMarkets.com
Spending on medicines and healthcare in Canada witnessed steady growth in 2017, reflecting strong potential for new medicine development, infrastructure building and new entry/expansion opportunities. This report focuses its attention on pharmaceutical market in Canada and presents market trends, drivers and challenges facing the R&D...
7/16/18 - 2018 and Beyond: Ireland Pharmaceutical & Healthcare Market Trends & Outlook Study to 2025 - ResearchAndMarkets.com
Spending on medicines and healthcare in Ireland witnessed steady growth in 2017, reflecting strong potential for new medicine development, infrastructure building and new entry/expansion opportunities. This report focuses its attention on pharmaceutical market in Ireland and presents market trends, drivers and challenges facing the R&D...
7/16/18 - 2018 Novel Therapies for Rare and Genetic Diseases: Unveiling One of the Most Promising Fields of Therapeutic Technology Synergy - ResearchAndMarkets.com
The "Novel Therapies for Rare and Genetic Diseases" report has been added to ResearchAndMarkets.com' s offering. Recent advancement in the development of novel platforms of smart targeting small molecules, gene therapy, stem cell therapy, gene modification, and gene rectification technologies pose new prospects for therapies and cures for rare and
7/16/18 - 21 Stocks Moving In Monday's Pre-Market Session
Gainers Tonix Pharmaceuticals Holding Corp. rose 29.2 percent to $5.10 in pre-market trading after the company disclosed that it has received Fast Track designation from the U.S. FDA for TNX-102 SL for the treatment of agitation in Alzheimer's disease. Coda Octopus Group, Inc. rose 26 percent to $4.71 in pre-market trading after the company disclos
7/16/18 - Abbott Laboratories Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jul. 3, 2018)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on July 3, 2018. The SEC file number is 0001179110-18-009367.. A U.S. Securities and Exchange Commission filing is a f
7/16/18 - ABBOTT RECEIVES FDA APPROVAL FOR NEXT-GENERATION MITRACLIP DEVICE TO TREAT PEOPLE WITH LEAKY HEART VALVES
ABBOTT PARK- Abbott today announced it received approval from the U.S. Food and Drug Administration for a next-generation version of its leading MitraClip heart valve repair device used to repair a leaky mitral valve without open-heart surgery. Abbott received CE Mark for the next-generation device earlier this year, allowing for sale of the device
7/16/18 - AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax
NORTH CHICAGO- AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid...
7/16/18 - Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
CAMBRIDGE- Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration has granted orphan drug designation for ACE-083, the Company's locally acting' Myostatin+' muscle agent, for the treat
7/16/18 - Acelrx Pharmaceuticals Inc. Files SEC Form 8-K, Current Report: (Jul. 2, 2018)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acelrx Pharmaceuticals Inc. was posted on July 2, 2018. The SEC file number is 0001437749-18-012799.. A U.S. Securities and Exchange Commission filin
7/16/18 - Acron Medical Announces FDA 510(k) Clearance of its Signature PEEK TLIF Interbody System, the ACRON Interbody.
Acron Medical, LLC, part of the spineMED Group, is a spine technology organization, dedicated to developing and commercializing globally innovative spinal implants. The company is proud to announce that it has received 510 clearance from the FDA for its signature new technology, the ACRON TLIF Interbody system. Andreas Bernegger, Acron Medical's Co
7/16/18 - Adial Pharmaceuticals, Inc. Files SEC Form S-1/A, General Form For Registration of Securities Under The Securities Act of 1933: (Jul. 3, 2018)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adial Pharmaceuticals, Inc. was posted on July 3, 2018. The SEC file number is 0001213900-18-008645.. A U.S. Securities and Exchange Commission filin
7/16/18 - Advaxis rises after FDA lifts clinical hold
Advaxis Inc. jumped $0.26 to $1.48 in morning trading Friday after it said FDA lifted a clinical hold on a Phase I/II combination study that includes the company's axalimogene filolisbac. Advaxis said Friday it is implementing new guidelines for early detection and treatment of safety-related events. On Tuesday, Advaxis said it has withdrawn the...
7/16/18 - Aerie Pharmaceuticals Announces Appointment of Randall Brown as Director, Payer Marketing
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Randall Brown as Director, Payer Marketing, reporting to Deanne Melloy, Aer
7/16/18 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Investigational Use
SUMMARY: The Food and Drug Administration is announcing that a proposed collection of information has been submitted to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995.. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed
7/16/18 - AIT Therapeutics Announces Human and In-Vitro Nitric Oxide (NO) Data Presented at the 3rd Annual World Bronchiectasis Conference
AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that in-vitro data, as well as data from its compassionate use study, were presente
7/16/18 - AixSwiss B.V. supplements go organic, giving Americans a new colon cleansing option with Nupure Colon Pure
AixSwiss B.V., manufacturers of Nupure Colon Pure, now provides organic dietary supplements meant for health-conscious consumers who care about the quality, safety, and effectiveness of their supplements, and according to the Council of Responsible Nutrition, that's about half of all men and women in America. In a study conducted by The Council o
7/16/18 - Ajay Singh of Slayback Pharma wins Ernst and Young's Entrepreneur Of The Year 2018 Award in Life Sciences Category in New Jersey
By a News Reporter-Staff News Editor at Pharma Business Week Slayback Pharma announced that Founder& CEO, Ajay Singh, of Slayback Pharma LLC is the winner of the 32nd Ernst and Young's Entrepreneur Of The Year 2018 Award in the Life Sciences category in New Jersey. Ajay Singh won the award at a special gala event on June 28 at the Hyatt Regenc
7/16/18 - Akorn Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Jul. 3, 2018)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Akorn Inc. was posted on July 3, 2018. The SEC file number is 0001171843-18-005035.. A U.S. Securities and Exchange Commission filing is a formal doc
7/16/18 - ALDEYRA THERAPEUTICS ANNOUNCES LAST PATIENT DOSED IN DRY EYE DISEASE PHASE 2B CLINICAL TRIAL
LEXINGTON- Aldeyra Therapeutics, Inc., a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced that the last patient has completed dosing in Aldeyra's randomized, double-masked, vehicle-controlled, multi-center, parallel-group Phase 2 b clinical trial.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415